PHARMACEUTICAL IP

  • Offering
    • Evolve AI
      • Albert (Validity)
        • Validity analysis
        • Albert Construe (Claim construction)
      • Popper (Prosecution)
      • Franklin (Publication review)
      • AI for Sequences
    • Fractional IP counsel
    • Services
      • AI guidance
      • Competitive intelligence
      • Deals
      • Due diligence
      • Freedom to operate
      • IP strategy and communication
      • Oppositions and appeals
      • Patent drafting
      • Patent prosecution
      • Trade secrets
    • Technologies
      • Pharmaceuticals
      • Biologics
      • Cell & gene therapy
      • AI drug discovery
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Fractional IP counsel
    • Fractional IP counsel
    • What is fractional IP counsel?
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Evolve AI
    • Albert (Validity)
      • Validity analysis
      • Albert Construe (Claim construction)
    • Popper (Prosecution)
    • Franklin (Publication review)
    • AI for Sequences
  • Technologies
    • Pharmaceuticals
      • Dosing regimens
      • Formulations
      • Life cycle management
      • New indications
      • Platform technologies
    • Biologics
      • Antibodies
      • Antibody-drug conjugates (ADCs)
      • T cell engagers (TCEs)
    • Cell & gene therapy
      • CAR-T cell therapies
      • Gene therapies
      • In vivo CAR-T
      • Lipid nanoparticles (LNPs)
      • Macrophages (CAR-M)
      • mRNA therapeutics
      • Regenerative cell therapies
    • AI drug discovery
  • Insights
    • Articles
    • Pharma IP Toolkit
    • Evolve Guides
    • Events & Webinars
    • Subscribe
  • About us
    • Our team
    • Recognition
    • Join us
    • Contact us
  • Offering
    • Evolve AI
      • Albert (Validity)
        • Validity analysis
        • Albert Construe (Claim construction)
      • Popper (Prosecution)
      • Franklin (Publication review)
      • AI for Sequences
    • Fractional IP counsel
    • Services
      • AI guidance
      • Competitive intelligence
      • Deals
      • Due diligence
      • Freedom to operate
      • IP strategy and communication
      • Oppositions and appeals
      • Patent drafting
      • Patent prosecution
      • Trade secrets
    • Technologies
      • Pharmaceuticals
      • Biologics
      • Cell & gene therapy
      • AI drug discovery
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Fractional IP counsel
    • Fractional IP counsel
    • What is fractional IP counsel?
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Evolve AI
    • Albert (Validity)
      • Validity analysis
      • Albert Construe (Claim construction)
    • Popper (Prosecution)
    • Franklin (Publication review)
    • AI for Sequences
  • Technologies
    • Pharmaceuticals
      • Dosing regimens
      • Formulations
      • Life cycle management
      • New indications
      • Platform technologies
    • Biologics
      • Antibodies
      • Antibody-drug conjugates (ADCs)
      • T cell engagers (TCEs)
    • Cell & gene therapy
      • CAR-T cell therapies
      • Gene therapies
      • In vivo CAR-T
      • Lipid nanoparticles (LNPs)
      • Macrophages (CAR-M)
      • mRNA therapeutics
      • Regenerative cell therapies
    • AI drug discovery
  • Insights
    • Articles
    • Pharma IP Toolkit
    • Evolve Guides
    • Events & Webinars
    • Subscribe
  • About us
    • Our team
    • Recognition
    • Join us
    • Contact us
  • Offering
  • What is fractional IP counsel?
  • Evolve AI
  • Technologies
  • Insights
  • Our team
  • Offering
  • What is fractional IP counsel?
  • Evolve AI
  • Technologies
  • Insights
  • Our team

Why patents matter: Understanding the importance of IP in the pharma industry

  • Technology: Pharmaceuticals
  • 23rd July 2025
Patents are core to the pharma industry. How does this translate into how the pharma industry thinks about IP?
Swarm of gold spheres with one large turquoise sphere at the centre on dark blue, Evolve abstract article image

Originally posted on IPKat.

The purpose of patents is to protect the market for a product. Within this context, pharmaceuticals is perhaps the industry in which the relationship between patents and commercialisation is most apparent. For pharma, understanding the IP is absolutely core to commercial forecasting and investment decisions. Similarly, within pharma, it is not possible to understand the importance of the IP without also understanding the broader commercial context in which the IP is considered and evaluated. 

Fractional IP counsel

Forecasting the cliff-edge

In the pharma industry, understanding how IP secures a return on investment is a key financial concept applicable to all types of drugs. The lengthy timelines and multimillion-dollar cost of bringing a drug to market necessitate robust strategies to ensure this return. Research and development costs are exceptionally high, increasing from pre-clinical stages into and through clinical trials, and continuing even after a product launches. This represents a huge investment which needs to be recovered. 

The pharmaceutical industry therefore has to think long-term. Companies and investors will not see any returns on investment for many years. It is therefore very important for pharma companies to forecast the return on investment expected many years in the future to justify the present day investment. A key consideration for all pharmaceutical and biopharmaceutical drug products is therefore the date on which market competition is expected to emerge, known as the loss of exclusivity (LoE) date. Once a drug is placed on the market, the innovator company will have until the LoE to recoup its return on investment before the market for the product is eroded. 

The LoE date is therefore fundamental for financially forecasting the likelihood of a return on investment for a drug product. This date is not only used to assist investment decisions on internal programmes but is also often incorporated into the royalty terms for licensed products. Every investment decision made by pharmaceutical companies, from funding new clinical trials to engaging in collaborations with new companies and pursuing acquisitions, depends heavily on the forecasted LoE date. Consequently, one of the very first questions an IP attorney will be asked about any new drug product or program is to establish the LoE date. In-house you are asked to predict and justify the LoE date as soon as the project team seeks any significant investment decision. You will then be asked to confirm if there are changes in the predicted LoE at regular intervals, including for any new investment decision and for all the commercially relevant countries, right up until the LoE date is reached. 

Calculating the loss of exclusivity date

Patents are the primary mechanism of ensuring market protection for a drug product. The core composition of matter patent for a new medicine will ideally be filed shortly before the product candidate enters the clinic. This action triggers a 20-year clock, ticking inexorably towards patent expiry. In addition to patent protection, LoE may also be determined by regulatory exclusivity, if this runs longer than the composition of matter protection. 

Before regulatory exclusivity or the core composition of matter patent for a drug product expires, the market for the innovator’s product is protected (assuming that the composition of matter is robust). Once the product is on the market, which may not be until 10 years after the drug first starts clinical trials, the innovator can begin to recoup their substantial investment. The product’s market share revenue typically increases over its protected lifetime such that the most profitable years for the drug are generally the final years of its exclusivity period. This brings us to the LoE date. 

Essential to understanding LoE is appreciating that a key feature of traditional small molecule drugs is the ease with which they can be copied. Generic companies can therefore be poised to bring their copies to market on the very day the market is no longer protected. As these generic versions of the drug launch at a lower price point, they can rapidly capture significant market share, which can then immediately and drastically erode the innovator’s revenue. Often, multiple generic manufacturers will launch at the same time, leading to aggressive price discounting among them, which further accelerates the precipitous drop in revenue for the original drug. For these reasons, one typically observes a steep “patent cliff” in revenue immediately following the LoE for a small molecule drug. The market for small molecules is thus understood based on the principle that these products are easy to define, easy to copy, and easy to manufacture. The primary risk to the market, therefore, comes from generics who will rely on the originator’s data package and launch immediately after the LoE date.

However, the situation is more complex for biologics. Because biologics such as monoclonal antibodies are harder to copy and more expensive to manufacture, we generally observe more of a “patent slope” than patent cliff after LoE. The slope is expected to be even less steep for advanced therapies given that they are even harder to copy and more expensive to manufacture. Interestingly, whilst there are a number of currently marketed biologics fast approaching their official LoE date, e.g. as determined by composition of matter expiry, for many of these drugs there are no biosimilars in development poised to launch once “LoE” occurs. This raises the question of whether a more nuanced approach is needed to forecast return on investment and LoE for biologics, which takes account of factors other than IP, such as the competitive landscape and manufacturing challenges associated with a product. 

Taking the global view

To add further complexity, LoE is a date that must be determined on a country-by-country basis. There is considerable geographical variation in LoE arising from jurisdictional differences in patent law, provisions for patent term extension and regulatory data protection. For example, in the US, new chemical entities receive five years of regulatory exclusivity, whilst biologics enjoy twelve years. In Europe, by contrast, all new drug products approved by the EMA currently receive ten years of regulatory protection. 

The provisions and rules by which a patent may be extended based on market approval for a drug product may also vary widely between jurisdictions. Many countries, including the US, European countries and Japan, offer a maximum term of 5 years of additional patent protection based on a first marketing authorisation for a drug product. However, there are very different rules between the jurisdictions on how this term is calculated. In other countries, no patent term extension may be available. All of this can lead to a situation in which LoE for a drug product may occur in one core market, years before LoE elsewhere. This is currently the situation for Novo Nordisk’s weight loss drug semaglutide, for which LoE in China is next year based on core patent expiry, whilst regulatory protection and patent term extensions protect the semaglutide market in Europe, US and Japan until at least 2031. 

Final thoughts 

The context of how patents are viewed in the pharma industry is critical to understanding the broader implications of any patent decision in the field. LoE currently provides the foundation for the financial forecasting upon which the entire pharma industry is built. However, despite the importance of the LoE date for all financial forecasting, there are many uncertainties associated with determining this date, particularly when looking more than twenty years into the future. To begin with, the legal and regulatory environment is in a constant state of flux. Patent law itself may change over the twenty-year life of a patent, potentially altering the scope or enforceability of the rights that were originally granted. These developments in patent law may lead, for example, to the invalidation of core composition of matter patents that have been the basis of LoE throughout the life cycle of a drug, see for example the recent AstraZeneca Forxiga case.

The regulatory environment is also subject to change. The European Union, for example, is currently considering significant reforms to its pharmaceutical legislation which may alter the periods of regulatory exclusivity available, and substantially impact the LoE date. Governments may also introduce new drug pricing initiatives, such as those seen recently in the US and those currently in force in Canada, which can profoundly impact the commercial viability of a product irrespective of its patent status. The LoE date may therefore also change over the life cycle of a drug. Whilst these uncertainties do not diminish the critical importance of the LoE date for forecasting, they nonetheless highlight the need for a dynamic and sophisticated IP strategy that can adapt to a changing legal, regulatory and commercial landscape. Additionally, in order to understand the potential impact of any patent decision in the pharma field, it is essential to consider how the IP fits within the commercial framework of the industry. 

Further reading

  • How to read a biotech patent
  • Freedom to operate versus patentability in biotech: What the difference is and why it matters
  • IP strategy for AI-assisted drug discovery
  • How do you calculate loss of exclusivity for a cell therapy? Patents versus regulatory exclusivity
  • Commercial success is a nothing-burger for the EPO in Wegovy patent inventive step analysis (T 1701/22, Obesity treatment with semaglutide)

Related insights...

Gold block of two interlocking pieces with a turquoise joint on dark blue, Evolve abstract article image.
Gold block of two interlocking pieces with a turquoise joint on dark blue, Evolve abstract article image.

Not just synergy: Other ways to support a drug combo invention (T 0593/24)

  • 17th November 2026
It is often necessary to support a drug combination invention with synergy data. This can be a problem for innovators, given that synergy data may not be assessed in the clinic, as additive effects may be sufficient for regulatory approval. However, T 0593/24 is a reminder that, if you lack synergy data, this may not…
Gold band splitting into three branches at a turquoise junction on dark blue, Evolve abstract article image
Gold band splitting into three branches at a turquoise junction on dark blue, Evolve abstract article image

Fractional IP counsel for biotech: what to look for in a fractional IP adviser

  • 16th November 2026
What to look for in part-time senior IP support for a growing biotech, from Series A to partnering and acquisition, and how experienced fractional IP counsel can help at every stage.
Stack of gold plates fanning open around a turquoise light on dark blue, Evolve abstract article image
Stack of gold plates fanning open around a turquoise light on dark blue, Evolve abstract article image

The enablement paradox and the danger of definitions (Wyeth v AstraZeneca)

  • 6th October 2026
The Federal Circuit’s decision in Wyeth v AstraZeneca (No. 2024-2325) applied the enablement test to a dose invention. The case is an interesting contrast to the other recent case to apply enablement to a method of treatment claim, Teva v Eli Lilly.
Gold block of two interlocking pieces with a turquoise joint on dark blue, Evolve abstract article image.
Gold block of two interlocking pieces with a turquoise joint on dark blue, Evolve abstract article image.

When do you file for a drug combination invention? (T 592/24)

  • 16th July 2026
Drug combination inventions are increasingly difficult to protect. File too early for a drug-combination invention and the application may lack the data to support the non-obvious effect of the combination. Wait for the trial read-out, and a competitor, or your own published protocol, may have already placed the invention in the public domain. 
Stack of gold slabs with a glowing turquoise middle layer on dark blue, Evolve abstract article image.
Stack of gold slabs with a glowing turquoise middle layer on dark blue, Evolve abstract article image.

Patenting the use of medical devices (T 0941/24)

  • 26th June 2026
Patenting medical devices in Europe is challenging. First, there is the problem that medical use claims are not permitted for medical devices, whilst simultaneously methods of treatment or surgery using a device are excluded from patentability. 
Stack of gold plates fanning open around a turquoise light on dark blue, Evolve abstract article image
Stack of gold plates fanning open around a turquoise light on dark blue, Evolve abstract article image

Mechanistic insights supporting the sufficiency and inventive step of a therapeutic use (without clinical data) (T 1601/22)

  • 24th February 2026
At the EPO, it is perfectly possible for a therapeutic invention to survive without clinical data. The recent decision in T 1601/22 confirmed this sometimes surprisingly low bar for sufficiency in Europe for therapeutic inventions.
Gold ball-and-stick molecule with one turquoise atom on dark blue, Evolve pharmaceuticals image
Gold ball-and-stick molecule with one turquoise atom on dark blue, Evolve pharmaceuticals image

EPO pharma case law trends 2025: Clinical inventions

  • 26th November 2025
The law in the pharma sector is also constantly evolving. Understanding the case law trends when drafting, prosecuting and defending these cases is therefore paramount. In our second post on EPO pharma case law trends in 2025, we review the most impactful decisions of the year relating to clinical-stage inventions. 
Flight of gold steps with one turquoise glowing step on dark blue, Evolve abstract article image
Flight of gold steps with one turquoise glowing step on dark blue, Evolve abstract article image

Sufficiency at the priority date: A study protocol is not “the same” as a therapeutic effect invention (T 0883/23)

  • 31st October 2025
Therapeutic inventions are generally not considered sufficiently disclosed absent supporting data. The recent decision in T 0883/23 found that this applies both at the priority date and the filing date of the patent.
Single cut gold stone glowing turquoise at its heart on dark blue, Evolve abstract article image
Single cut gold stone glowing turquoise at its heart on dark blue, Evolve abstract article image

Patentee’s own post-published data undermines the credibility of their broad cat antibody patent (T 0709/23)

  • 27th October 2025
How early is too early to file a biotech patent? EPO decision T 0709/23 provides a costly answer, demonstrating the fatal risks of claiming a broad therapeutic use before the link between structure, function, and actual effect is truly understood.
Gold strands braiding into one cord with a turquoise join on dark blue, Evolve abstract article image
Gold strands braiding into one cord with a turquoise join on dark blue, Evolve abstract article image

From oil to gemstones: Our shifting understanding of the value of data

  • 10th October 2025
The concept of data as oil has been around for a number of years, but does the analogy still hold? In the pharma and biotech industry, there is now a shift away from thinking of data as a bulk commodity of raw material, towards the pursuit of high quality data that can improve the performance…
All Insights

evolve® is a trading entity of Evolve Intellectual Property Limited. Evolve Intellectual Property Limited is regulated by the Intellectual Property Regulation Board (IPReg). Details of the UK professional rules can be found on the IPReg website

registered address: 49 Greek Street, London, England, W1D 4EG

website out of house

© 2026 All Rights Reserved

Keep in touch

  • Subscribe
  • Contact us
  • Cookie Notice
  • Complaints Procedure
  • Privacy notice
  • Subscribe
  • Contact us
  • Cookie Notice
  • Complaints Procedure
  • Privacy notice